Scarica l'app Stockscreener
76.99
1.69%
1.28
Dopo l'orario di chiusura:
77.20
0.21
+0.27%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$75.71
Aprire:
$73.55
Volume 24 ore:
552.44K
Relative Volume:
0.51
Capitalizzazione di mercato:
$2.21B
Reddito:
$55.23M
Utile/perdita netta:
$-164.08M
Rapporto P/E:
-11.25
EPS:
-6.8461
Flusso di cassa netto:
$-208.68M
1 W Prestazione:
+8.48%
1M Prestazione:
+12.62%
6M Prestazione:
+27.26%
1 anno Prestazione:
+11,583%
Intervallo 1D:
$73.04
$78.00
Intervallo di 1 settimana:
$64.10
$78.81
Portata 52W:
$0.432
$78.81
Nektar Therapeutics Stock (NKTR) Company Profile
Nome
Nektar Therapeutics
Settore
Industria
Telefono
(415) 482-5300
Indirizzo
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
76.99 | 2.21B | 55.23M | -164.08M | -208.68M | -6.8461 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Iniziato | Wedbush | Neutral |
| 2026-03-17 | Iniziato | TD Cowen | Buy |
| 2026-02-10 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-11-26 | Iniziato | Citigroup | Buy |
| 2025-06-24 | Reiterato | BTIG Research | Buy |
| 2025-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2025-04-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-03-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Iniziato | B. Riley Securities | Buy |
| 2024-12-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-04 | Iniziato | Piper Sandler | Overweight |
| 2024-09-30 | Ripresa | BTIG Research | Buy |
| 2024-06-28 | Iniziato | Rodman & Renshaw | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-11-09 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-02-24 | Downgrade | Jefferies | Hold → Underperform |
| 2022-08-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Ripresa | Jefferies | Hold |
| 2022-04-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-03-15 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-15 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-03-14 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Downgrade | Stifel | Buy → Hold |
| 2022-03-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Iniziato | BofA Securities | Neutral |
| 2021-06-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-02-22 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-09-14 | Iniziato | JP Morgan | Neutral |
| 2020-06-10 | Downgrade | CFRA | Hold → Sell |
| 2020-05-12 | Reiterato | H.C. Wainwright | Neutral |
| 2020-04-22 | Iniziato | The Benchmark Company | Buy |
| 2020-03-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-08 | Downgrade | Goldman | Buy → Sell |
| 2019-08-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-09 | Downgrade | Mizuho | Buy → Neutral |
| 2019-03-15 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-06-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Reiterato | H.C. Wainwright | Buy |
| 2018-04-20 | Iniziato | Seaport Global Securities | Buy |
| 2018-04-13 | Ripresa | Piper Jaffray | Overweight |
| 2018-04-06 | Reiterato | Mizuho | Buy |
| 2018-04-02 | Ripresa | H.C. Wainwright | Buy |
Mostra tutto
Nektar Therapeutics Borsa (NKTR) Ultime notizie
Nektar Therapeutics (NKTR) Is Up 12.1% After REZPEG Data And Lawsuits CollideHas The Bull Case Changed? - finance.yahoo.com
Do Rezpegaldesleukin Lawsuits Reframe Nektar Therapeutics' (NKTR) Core Risk Narrative Around Trial Integrity? - simplywall.st
NKTR PE Ratio & Valuation, Is NKTR Overvalued - Intellectia AI
NKTR SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - ChartMill
Nektar Therapeutics at TD Cowen Conference: Immunology Focus - Investing.com
Class Actions Challenge Nektar Trial Disclosures And Investor Confidence Narrative - Sahm
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics - GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Inc.
Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Stock Decline - TipRanks
Assessing Nektar Therapeutics (NKTR) Valuation After A Sharp Multi‑Month Share Price Run - Sahm
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics ... - bdtonline.com
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein - GlobeNewswire
NKTR SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) ... - Bluefield Daily Telegraph
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain OfficersNKTR - PR Newswire
NKTR Stock Price, Quote & Chart | NEKTAR THERAPEUTICS (NASDAQ:NKTR) - ChartMill
Nektar Therapeutics (NASDAQ:NKTR) Hits New 52-Week HighHere's Why - MarketBeat
Oppenheimer reiterates Nektar stock rating on alopecia data - Investing.com
Oppenheimer on Nektar Therapeutics (NKTR): 'meaningful opportunities for biologics in AA' - StreetInsider
Why Nektar Therapeutics Stock Is Surging Higher Today - TipRanks
NKTR Investor Alert: Nektar Therapeutics Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards - marketscreener.com
NEKTAR THERAPEUTICS NEKTAR THER (0UNL.L) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Nektar Therapeutics Bets Big on Respag Phase 3 - TipRanks
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel ... - Caledonian Record
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Nektar - GlobeNewswire
Nektar Therapeutics Shareholders Urged to Seek Compensation for Losses - National Today
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR - ChartMill
NKTR Stockholders Have Rights – If You Lost Money Investing in Nektar Therapeutics Contact ... - Caledonian Record
NKTR Stockholders Have Rights – If You Lost Money Investing - GlobeNewswire
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Nektar Showcases Rezpegaldesleukin Data As Phase 3 And Valuation Loom - simplywall.st
NKTR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Nektar Therapeutics Securities Lawsuit -- The Gross Law Firm - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Secu - GuruFocus
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit - ChartMill
NKTR Investor Alert: Nektar Therapeutics Securities Fraud - GlobeNewswire
REZOLVE-AD: Rezpegaldesleukin Shows Consistent Efficacy Across Atopic Dermatitis Severity, With Raj Chovatiya, MD, PhD - hcplive.com
Portnoy Law Firm Announces Class Action on Behalf of Nektar Therapeutics, Inc. Investors - GlobeNewswire
Nektar announces data from Phase 2b Rezolve-AD, Rezolve-AA studies - TipRanks
NKTR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Nektar Therape - gurufocus.com
NKTR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - PR Newswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel ... - Black Hills Pioneer
Nektar presents rezpegaldesleukin data at dermatology meeting By Investing.com - Investing.com Australia
Nektar Therapeutics (NASDAQ:NKTR) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Nektar Q4 earnings & revenues trump estimates, pipeline in focus - MSN
First in Class Rezpegaldesleukin: Favorable Safety, Durable Responses in Alopecia Areata, With David Rosmarin, MD - HCPLive
ROSEN, LEADING INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Nektar presents rezpegaldesleukin data at dermatology meeting - Investing.com
Nektar’s eczema drug also cut hair-loss scores in 36-week study - stocktitan.net
ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class ActionNKTR - ACCESS Newswire
Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting - Sahm
Nektar Therapeutics Azioni (NKTR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):